Compared with whole brain radiation, stereotactic radiation reduces the rates of neurologic deaths in patients with SCLC and ...

Among the 47.2% of patients who had twice-daily radiation, median overall survival was 35.4 months vs 28.3 months in those who received once-daily radiation (HR, 1.44; 95% CI, 1.10-1.89).

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent ...

Between 2018 and 2023, 100 patients with small cell lung cancer and 1-10 brain metastases were enrolled in this single arm, multi-center, phase 2 trial of stereotactic treatment.

2. Three Fractionated SRS Treatments Versus One MSK is a participating institution in a large, phase 3 trial testing fractionated SRS versus standard SRS in patients with intact brain metastases ...

SCLC is a rare but aggressive cancer that makes up roughly 10% to 15% of lung cancers. It gets its name from the microscopic appearance of cancer cells. It’s highly linked to smoking. SCLC ...

Treatment of limited-stage small cell lung cancer (LS-SCLC) with twice-a-day radiation therapy (RT) has remained the standard of care for many decades. Growing evidence suggests that outcomes with ...

What’s the life expectancy for people with small cell lung cancer? The 5-year relative survival rate for SCLC in the United States was 8.6% from 2014 to 2020.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...

Source Reference: Higgins KA, et al "Concurrent chemoradiation +/- atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology/Alliance LU005" ASTRO 2024; Abstract PL-04.